Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$20.18
+10.1%
$18.99
$14.40
$47.00
$1.34B1.39890,309 shs1.01 million shs
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$79.52
-2.7%
$99.15
$75.00
$126.89
$5.45B0.23973,734 shs2.17 million shs
Neogen Co. stock logo
NEOG
Neogen
$6.50
+8.9%
$7.04
$3.87
$18.58
$1.41B1.832.95 million shs7.28 million shs
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
$8.55
+5.3%
$8.13
$5.90
$28.18
$885.64M2.332.48 million shs3.87 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
0.00%-11.28%+8.85%-14.86%-54.08%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
0.00%-24.72%-19.75%-5.81%+7.68%
Neogen Co. stock logo
NEOG
Neogen
0.00%+3.83%+6.99%-42.71%-51.58%
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
0.00%-8.14%+9.58%-15.24%-66.80%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
1.506 of 5 stars
4.50.00.00.01.80.00.0
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
4.363 of 5 stars
3.51.00.04.22.62.51.9
Neogen Co. stock logo
NEOG
Neogen
3.4878 of 5 stars
3.32.00.00.02.43.32.5
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
4.5083 of 5 stars
4.31.00.04.72.02.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
2.90
Moderate Buy$53.90167.10% Upside
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
3.00
Buy$132.6766.83% Upside
Neogen Co. stock logo
NEOG
Neogen
2.50
Moderate Buy$9.0038.46% Upside
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
2.67
Moderate Buy$36.90331.58% Upside

Current Analyst Ratings Breakdown

Latest NTLA, NEOG, LNTH, and CLDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/12/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$55.00 ➝ $45.00
5/9/2025
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$44.00 ➝ $38.00
5/9/2025
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$36.00 ➝ $31.00
5/9/2025
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$46.00 ➝ $43.00
5/9/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$14.00 ➝ $10.00
5/9/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$68.00 ➝ $68.00
5/8/2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$127.00 ➝ $117.00
5/6/2025
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
4/28/2025
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$64.00
4/22/2025
Neogen Co. stock logo
NEOG
Neogen
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$6.40 ➝ $5.00
4/21/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradePeer Perform ➝ Outperform$21.00
(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$7.02M190.83N/AN/A$9.08 per share2.22
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.54B3.54$6.64 per share11.98$11.91 per share6.68
Neogen Co. stock logo
NEOG
Neogen
$906.00M1.56$0.66 per share9.80$14.52 per share0.45
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
$57.88M15.30N/AN/A$11.73 per share0.73
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$141.43M-$2.70N/AN/AN/A-1,544.32%-19.75%-18.86%N/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$326.66M$3.5213.2312.60N/A28.57%44.29%23.52%7/30/2025 (Estimated)
Neogen Co. stock logo
NEOG
Neogen
-$9.42M-$2.23N/A13.27N/A-52.12%2.89%1.98%7/29/2025 (Estimated)
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
-$481.19M-$5.25N/AN/AN/AN/A-49.34%-40.27%N/A

Latest NTLA, NEOG, LNTH, and CLDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$0.75-$0.81-$0.06-$0.81$1.08 million$0.70 million
5/8/2025Q1 2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
-$1.26-$1.10+$0.16-$1.10$11.39 million$16.63 million
5/7/2025Q1 2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.64$1.53-$0.11$1.02$377.37 million$372.76 million
4/9/2025Q3 2025
Neogen Co. stock logo
NEOG
Neogen
$0.12$0.10-$0.02-$0.05$225.27 million$221.00 million
2/27/2025Q4 2024
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$0.73-$0.71+$0.02-$0.71$1.25 million$1.18 million
2/27/2025Q4 2024
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.57$1.34-$0.23-$0.17$376.61 million$391.11 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/AN/AN/AN/AN/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
N/AN/AN/AN/AN/A
Neogen Co. stock logo
NEOG
Neogen
N/AN/AN/AN/AN/A
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/A
24.27
24.27
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
N/A
1.65
1.56
Neogen Co. stock logo
NEOG
Neogen
0.33
3.77
2.46
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
N/A
6.73
6.73

Institutional Ownership

CompanyInstitutional Ownership
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
99.06%
Neogen Co. stock logo
NEOG
Neogen
96.73%
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
88.77%

Insider Ownership

CompanyInsider Ownership
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
3.80%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
1.50%
Neogen Co. stock logo
NEOG
Neogen
1.13%
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
3.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
15066.38 million63.82 millionOptionable
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
70068.48 million68.48 millionOptionable
Neogen Co. stock logo
NEOG
Neogen
2,110217.04 million214.49 millionOptionable
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
600103.58 million98.59 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Celldex Therapeutics stock logo

Celldex Therapeutics NASDAQ:CLDX

$20.18 +1.85 (+10.09%)
Closing price 04:00 PM Eastern
Extended Trading
$22.08 +1.90 (+9.42%)
As of 06:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Lantheus stock logo

Lantheus NASDAQ:LNTH

$79.52 -2.22 (-2.72%)
Closing price 04:00 PM Eastern
Extended Trading
$79.55 +0.03 (+0.04%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Neogen stock logo

Neogen NASDAQ:NEOG

$6.50 +0.53 (+8.88%)
Closing price 04:00 PM Eastern
Extended Trading
$6.76 +0.26 (+3.92%)
As of 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods. The segment offers its products primarily to milling and grain, meat and poultry, prepared foods and ingredients, fruits and vegetables, seafood, dairy, beverage, water, healthcare, traditional culture media markets, food service, and dietary supplements markets. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products, and genomics testing services marketed through veterinarians, retailers, livestock producers, and animal health product distributors, for the animal safety market. The segment offers its products for companion animal veterinarians; livestock producers, veterinarians, and breed associations; retailers; breeding and genetics companies; diagnostic labs and universities; distributors; and other manufacturers and government agencies. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.

Intellia Therapeutics stock logo

Intellia Therapeutics NASDAQ:NTLA

$8.55 +0.43 (+5.30%)
Closing price 04:00 PM Eastern
Extended Trading
$8.63 +0.08 (+0.92%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.